Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02209519 · ClinicalTrials.gov registry record · Phase 3
Randomized Controlled Trial of Treatment of Male Partners of Women With BV
A Phase 3 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 3
- Development phase
- 214
- Enrollment target
NCT02209519 is a Phase 3 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 214 participants.
The verdict
NCT02209519, a Phase 3 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 214 participants
- Enrollment target
Study Summary
Male partners of womoen with recurrent bacteria vaginosis are randomized to treatment with metronidazole or placebo to compare the rates of recurrent BV in the women
Interventions
- DRUG Metronidazole (male partner)
- OTHER Placeob (male partner)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2015-02 |
| Est. Completion | 2019-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02209519
The ClinicalTrials.gov registry entry for NCT02209519 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Metronidazole (male partner) is the first listed.
NCT02209519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02209519 about?
NCT02209519 is a clinical study titled "Randomized Controlled Trial of Treatment of Male Partners of Women With BV". Male partners of womoen with recurrent bacteria vaginosis are randomized to treatment with metronidazole or placebo to compare the rates of recurrent BV in the women
What is the current status of trial NCT02209519?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 214 participants. The study started on 2015-02. Estimated completion is 2019-03.
What interventions are being tested in trial NCT02209519?
The interventions under investigation include: Metronidazole (male partner) (DRUG), Placeob (male partner) (OTHER).
Who is sponsoring clinical trial NCT02209519?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.